PURPOSE: Obesity increases the risk of death from many malignancies, including non-Hodgkin's lymphoma (NHL). In diffuse large B-cell lymphoma (DLBCL), the most common form of NHL, the association between body mass index (BMI) at diagnosis and survival is unclear. PATIENTS AND METHODS: We evaluated the association between BMI at diagnosis and overall survival in a retrospective cohort of 2,534 United States veterans diagnosed with DLBCL between October 1, 1998 and December 31, 2008. Cox modeling was used to control for patient- and disease-related prognostic variables. RESULTS: Mean age at diagnosis was 68 years (range, 20 to 100 years); 64% of patients were overweight (BMI, 25 to < 30) or obese (BMI, ≥ 30). Obese patients were significantly younger, had significantly fewer B symptoms, and trended toward lower-stage disease, compared with other BMI groups. Cox analysis showed reduced mortality in overweight and obese patients (overweight: hazard ratio [HR], 0.73; 95% CI, 0.65 to 0.83; obese: HR, 0.68; 95% CI, 0.58 to 0.80), compared with normal-weight patients (BMI, 18.5 to < 25). Treatment during the rituximab era reduced the risk of death without affecting the association between BMI and survival. Disease-related weight loss occurred in 29% of patients with weight data 1 year before diagnosis. Cox analysis based on BMI 1 year before diagnosis continued to demonstrate reduced risk of death in overweight and obese patients. CONCLUSION: Being overweight or obese at the time of DLBCL diagnosis is associated with improved overall survival. Understanding the mechanisms responsible for this association will require further study.
PURPOSE: Obesity increases the risk of death from many malignancies, including non-Hodgkin's lymphoma (NHL). In diffuse large B-cell lymphoma (DLBCL), the most common form of NHL, the association between body mass index (BMI) at diagnosis and survival is unclear. PATIENTS AND METHODS: We evaluated the association between BMI at diagnosis and overall survival in a retrospective cohort of 2,534 United States veterans diagnosed with DLBCL between October 1, 1998 and December 31, 2008. Cox modeling was used to control for patient- and disease-related prognostic variables. RESULTS: Mean age at diagnosis was 68 years (range, 20 to 100 years); 64% of patients were overweight (BMI, 25 to < 30) or obese (BMI, ≥ 30). Obesepatients were significantly younger, had significantly fewer B symptoms, and trended toward lower-stage disease, compared with other BMI groups. Cox analysis showed reduced mortality in overweight and obesepatients (overweight: hazard ratio [HR], 0.73; 95% CI, 0.65 to 0.83; obese: HR, 0.68; 95% CI, 0.58 to 0.80), compared with normal-weight patients (BMI, 18.5 to < 25). Treatment during the rituximab era reduced the risk of death without affecting the association between BMI and survival. Disease-related weight loss occurred in 29% of patients with weight data 1 year before diagnosis. Cox analysis based on BMI 1 year before diagnosis continued to demonstrate reduced risk of death in overweight and obesepatients. CONCLUSION: Being overweight or obese at the time of DLBCL diagnosis is associated with improved overall survival. Understanding the mechanisms responsible for this association will require further study.
Authors: Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet Journal: Blood Date: 2005-09-08 Impact factor: 22.113
Authors: Relin Yang; Michael C Cheung; Felipe E Pedroso; Margaret M Byrne; Leonidas G Koniaris; Teresa A Zimmers Journal: J Surg Res Date: 2011-05-23 Impact factor: 2.192
Authors: Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun Journal: N Engl J Med Date: 2010-12-02 Impact factor: 91.245
Authors: Susan M Geyer; Lindsay M Morton; Thomas M Habermann; Cristine Allmer; Scott Davis; Wendy Cozen; Richard K Severson; Charles F Lynch; Sophia S Wang; Matthew J Maurer; Patricia Hartge; James R Cerhan Journal: Cancer Date: 2010-06-15 Impact factor: 6.860
Authors: Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger Journal: Blood Date: 2007-03-27 Impact factor: 22.113
Authors: F Hong; T M Habermann; L I Gordon; H Hochster; R D Gascoyne; V A Morrison; R I Fisher; N L Bartlett; P J Stiff; B D Cheson; M Crump; S J Horning; B S Kahl Journal: Ann Oncol Date: 2014-03 Impact factor: 32.976
Authors: Arun Ganti; Weijian Liu; Suhong Luo; Kristen M Sanfilippo; Ryan Roop; Ryan Lynch; Peter Riedell; Katiuscia O'Brian; Graham A Colditz; Kenneth R Carson Journal: Br J Haematol Date: 2014-07-15 Impact factor: 6.998
Authors: Da Jung Kim; Taeyun Kim; Jee-Yeong Jeong; Jae-Cheol Jo; Won Sik Lee; Ho-Jin Shin; Ji Hyun Lee; Ho Sup Lee Journal: Int J Hematol Date: 2020-01-06 Impact factor: 2.490
Authors: Tracey S Beason; Su-Hsin Chang; Kristen M Sanfilippo; Suhong Luo; Graham A Colditz; Ravi Vij; Michael H Tomasson; John F Dipersio; Keith Stockerl-Goldstein; Arun Ganti; Tanya Wildes; Kenneth R Carson Journal: Oncologist Date: 2013-09-18
Authors: Zheng Zhou; Alfred W Rademaker; Leo I Gordon; Ann S LaCasce; Allison Crosby-Thompson; Ann Vanderplas; Gregory A Abel; Maria A Rodriguez; Auayporn Nademanee; Mark S Kaminski; Myron S Czuczman; Michael M Millenson; Andrew D Zelenetz; Joyce Niland; Jonathan W Friedberg; Jane N Winter Journal: J Natl Compr Canc Netw Date: 2016-10 Impact factor: 11.908
Authors: Ulrich Jaeger; Marek Trneny; Helen Melzer; Michael Praxmarer; Weerasak Nawarawong; Dina Ben Yehuda; David Goldstein; Bilijana Mihaljevic; Osman Ilhan; Veronika Ballova; Michael Hedenus; Liang-Tsai Hsiao; Wing-Yan Au; Sonja Burgstaller; Gerhard Weidinger; Felix Keil; Christian Dittrich; Cathrin Skrabs; Anton Klingler; Andreas Chott; Michael A Fridrik; Richard Greil Journal: Haematologica Date: 2015-04-24 Impact factor: 9.941
Authors: Andrew M Brunner; Hossein Sadrzadeh; Yang Feng; Benjamin J Drapkin; Karen K Ballen; Eyal C Attar; Philip C Amrein; Steven L McAfee; Yi-Bin Chen; Donna S Neuberg; Amir T Fathi Journal: Am J Hematol Date: 2013-05-30 Impact factor: 10.047